| Listed site | cro | cro |
|---|
| Summary | Bioanalytical CRO specializing in PK/PD, biomarker, and spatial imaging services across discovery through Phase 3 clinical trials, with 20+ years of regulatory expertise. | Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries. |
|---|
| Services | - LC-MS Bioanalysis (Small Molecule)
- Bioanalysis
- Biomarker Assays
- Pathology & Histology Services
- In Vivo PK / PD Studies
- GLP Toxicology
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Discovery Research
- Translational Research
- Regulatory Affairs
- In Vivo Efficacy Models
- Preclinical In Vivo Studies
- Target Identification & Validation
- Clinical Imaging Core Lab
- Ligand-Binding Bioanalysis (Large Molecule)
| - Discovery Research
- Target Identification & Validation
- High-Throughput Screening
- Medicinal Chemistry
- Computational & In-Silico Drug Discovery
- Protein Engineering
- Preclinical In Vitro Studies
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Carcinogenicity Studies
- DART (Reproductive & Developmental Toxicology)
- Specialized & Large-Animal Models
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Medical Writing
- Pharmacovigilance & Drug Safety
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Analytical Method Development & Validation
- ICH Stability Studies
- Translational Research
|
|---|
| Modalities | - Small Molecule
- Biologics (Monoclonal Antibodies)
- Antibody-Drug Conjugate (ADC)
- Oligonucleotide
- Peptide
| - Small Molecule
- Peptide
- Oligonucleotide
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Antibody-Drug Conjugate (ADC)
- mRNA
- Cell Therapy
- Gene Therapy
- Vaccine
|
|---|
| Indications | Data not yet provided. | - Oncology
- Immunology
- Neurology
- Psychiatry
- Metabolic
- Cardiovascular
- Infectious Disease
- Rare Disease
- Respiratory
- Dermatology
- Ophthalmology
- Gastroenterology
- Nephrology
- Women's Health
|
|---|
| Locations | - Headquarters, Colorado Springs, Colorado, United States
- Utah, Salt Lake City, Utah, United States
- France, Loos, Hauts-de-France, France
- Office, Salt Lake City, Utah, United States
- Office, Loos, Nord, France
- Salt Lake City, Salt Lake City, Utah, United States
- Loos, Loos, Hauts-de-France, France
| - Headquarters, Shanghai, Pudong, China
- Global Operations, Asia, Europe, North America
|
|---|
| Certifications | Data not yet provided. | Data not yet provided. |
|---|
| Reviews | Review summary appears after site-level review signal gate opens. | Review summary appears after site-level review signal gate opens. |
|---|